The Institute of Life Sciences (ILS), which functions under the Department of Biotechnology, has entered into a non-exclusive license for product commercialisation after having successfully developed antibodies against the Chikungunya viral (CHIKV) infection.
The antibodies were developed following decade-long research on the CHIKV infection at the ILS laboratory headed by Dr. Soma Chattopadhyay, a senior molecular virologist. In fact, Dr. Chattopadhyay has been selected for the Biotech Product, Process Development and Commercialisation Award 2019 by the Department of Biotechnology.
The ILS will partner with a biotechnology-based company for product commercialisation and marketing of antibodies in a 60:40 profit sharing basis.
“With no prior antibodies reported against CHIKV, Dr. Chattopadhyay’s group was the first to develop and characterize novel, highly sensitive and specific polyclonal antibodies against the non-structural proteins – nsP1, nsP3 and nsP4 of CHIKV. Furthermore, her laboratory has also developed and characterized a monoclonal antibody against nsP2 of CHIKV,” said ILS in a statement.